| Compendium of current complement therapeutics WM Zelek, L Xie, BP Morgan, CL Harris Molecular immunology 114, 341-352, 2019 | 139 | 2019 |
| Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report MS Buckland, JB Galloway, CN Fhogartaigh, L Meredith, NM Provine, ... Nature communications 11 (1), 6385, 2020 | 112 | 2020 |
| Complement system biomarkers in first episode psychosis M Kopczynska, W Zelek, S Touchard, F Gaughran, M Di Forti, V Mondelli, ... Schizophrenia Research 204, 16-22, 2019 | 74 | 2019 |
| Complement inhibition with the C5 blocker LFG316 in severe COVID-19 WM Zelek, J Cole, MJ Ponsford, RA Harrison, BE Schroeder, N Webb, ... American Journal of Respiratory and Critical Care Medicine 202 (9), 1304-1308, 2020 | 56 | 2020 |
| SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies CA Fielding, P Sabberwal, JC Williamson, EJD Greenwood, TWM Crozier, ... Elife 11, e74489, 2022 | 47 | 2022 |
| Complement system biomarkers in epilepsy M Kopczynska, WM Zelek, S Vespa, S Touchard, M Wardle, S Loveless, ... Seizure 60, 1-7, 2018 | 38 | 2018 |
| The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery E Syrimi, E Fennell, A Richter, P Vrljicak, R Stark, S Ott, PG Murray, ... Iscience 24 (11), 2021 | 36 | 2021 |
| Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models SM Carpanini, M Torvell, RJ Bevan, RAJ Byrne, N Daskoulidou, T Saito, ... Acta Neuropathologica Communications 10 (1), 99, 2022 | 35 | 2022 |
| Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens SJ Moat, WM Zelek, E Carne, MJ Ponsford, K Bramhall, S Jones, ... Annals of Clinical Biochemistry 58 (2), 123-131, 2021 | 33 | 2021 |
| Cerebrospinal fluid complement system biomarkers in demyelinating disease WM Zelek, D Fathalla, A Morgan, S Touchard, S Loveless, E Tallantyre, ... Multiple Sclerosis Journal 26 (14), 1929-1937, 2020 | 30 | 2020 |
| Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species WM Zelek, BP Morgan Frontiers in Immunology 11, 612402, 2020 | 23 | 2020 |
| Characterizing a pH‐switch anti‐C5 antibody as a tool for human and mouse complement C5 purification and cross‐species inhibition of classical and reactive lysis WM Zelek, M Stott, D Walters, CL Harris, BP Morgan Immunology 155 (3), 396-403, 2018 | 23 | 2018 |
| Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID‐19 MK Siggins, K Davies, R Fellows, RS Thwaites, JK Baillie, MG Semple, ... Immunology 168 (3), 473-492, 2023 | 21 | 2023 |
| Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers MJ Scurr, WM Zelek, G Lippiatt, M Somerville, SEA Burnell, L Capitani, ... Immunology 165 (2), 250-259, 2022 | 21 | 2022 |
| Development and characterization of novel anti‐C5 monoclonal antibodies capable of inhibiting complement in multiple species WM Zelek, PR Taylor, BP Morgan Immunology 157 (4), 283-295, 2019 | 21 | 2019 |
| Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers WM Zelek, CL Harris, BP Morgan Immunobiology 223 (12), 744-749, 2018 | 21 | 2018 |
| Targeting complement in neurodegeneration: challenges, risks, and strategies WM Zelek, BP Morgan Trends in Pharmacological Sciences 43 (8), 615-628, 2022 | 20 | 2022 |
| Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know WM Zelek, RA Harrison Immunobiology 228 (3), 152393, 2023 | 17 | 2023 |
| Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study I Murrell, D Forde, W Zelek, L Tyson, L Chichester, N Palmer, R Jones, ... PLoS One 16 (1), e0245382, 2021 | 16 | 2021 |
| The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade O McMahon, TM Hallam, S Patel, CL Harris, A Menny, WM Zelek, ... Human molecular genetics 30 (13), 1188-1199, 2021 | 15 | 2021 |
